Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of persistent B19 parvovirus infection in AIDS.
Ramratnam B, Gollerkeri A, Schiffman FJ, Rintels P, Flanigan TP. Ramratnam B, et al. Among authors: gollerkeri a. Br J Haematol. 1995 Sep;91(1):90-2. doi: 10.1111/j.1365-2141.1995.tb05250.x. Br J Haematol. 1995. PMID: 7577659
A study of cross-coverage calls.
Ramratnam B, Gollerkeri A, Martens P, Schiffman FJ, Parameswaran J. Ramratnam B, et al. Among authors: gollerkeri a. J Gen Intern Med. 1996 Mar;11(3):189. doi: 10.1007/BF02600277. J Gen Intern Med. 1996. PMID: 8667101 No abstract available.
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial.
Ackerman L, Acloque G, Bacchelli S, Schwartz H, Feinstein BJ, La Stella P, Alavi A, Gollerkeri A, Davis J, Campbell V, McDonald A, Agarwal S, Karnik R, Shi K, Mishkin A, Culbertson J, Klaus C, Enerson B, Massa V, Kuhn E, Sharma K, Keaney E, Barnes R, Chen D, Zheng X, Rong H, Sabesan V, Ho C, Mainolfi N, Slavin A, Gollob JA. Ackerman L, et al. Among authors: gollerkeri a. Nat Med. 2023 Dec;29(12):3127-3136. doi: 10.1038/s41591-023-02635-7. Epub 2023 Nov 13. Nat Med. 2023. PMID: 37957373 Free PMC article. Clinical Trial.
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Tabernero J, et al. Among authors: gollerkeri a. ESMO Open. 2021 Dec;6(6):100328. doi: 10.1016/j.esmoop.2021.100328. Epub 2021 Dec 9. ESMO Open. 2021. PMID: 34896698 Free PMC article. Review.
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128].
Gogas H, Dummer R, Ascierto PA, Arance A, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, de Willem GJ, Sellier AT, Suissa J, Murris J, Gollerkeri A, Robert C, Flaherty KT. Gogas H, et al. Among authors: gollerkeri a. Eur J Cancer. 2022 Jan;160:287-288. doi: 10.1016/j.ejca.2021.10.002. Epub 2021 Oct 28. Eur J Cancer. 2022. PMID: 34756500 No abstract available.
22 results